Gilead Sciences, Inc. reported 5 holdings worth US$1.65B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 3, 2026
Gilead Sciences, Inc. reported 5 holdings worth US$1.65B as of Jun 30, 2026. Largest: Arcus Biosciences, Inc., Lakefront Biotherapeutics and Assembly Biosciences, Inc. Filed Aug 3, 2026 (Form 13F).
- Holdings
- 5
- Value as reported
- US$1.65B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Arcus Biosciences, Inc. | 31.4M | US$969M | 58.8% |
| Lakefront Biotherapeutics | 16.7M | US$500M | 30.3% |
| Assembly Biosciences, Inc. | 4.98M | US$137M | 8.3% |
| Kyverna Therapeutics, Inc. | 4.13M | US$36.8M | 2.2% |